Outcomes in children who underwent transplantation for autoimmune hepatitis

Steven R. Martin, Fernando Alvarez, Ravinder Anand, Changhong Song, Wanrong Yin – 6 January 2011 – The outcomes of 113 children with autoimmune hepatitis (AIH), registered with Studies of Pediatric Liver Transplantation and who underwent transplantation between 1995 and 2006, were compared with those who underwent transplantation for other diagnoses (non‐AIH). A total of 4.9% of liver transplants were for AIH; 81% of these patients had AIH type 1 and most underwent transplantation for complications of chronic disease (60%), the majority in females (72%).

The GRACILE mutation introduced into Bcs1l causes postnatal complex III deficiency: A viable mouse model for mitochondrial hepatopathy

Per Levéen, Heike Kotarsky, Matthias Mörgelin, Riitta Karikoski, Eskil Elmér, Vineta Fellman – 28 December 2010 – Mitochondrial dysfunction is an important cause for neonatal liver disease. Disruption of genes encoding oxidative phosphorylation (OXPHOS) components usually causes embryonic lethality, and thus few disease models are available. We developed a mouse model for GRACILE syndrome, a neonatal mitochondrial disease with liver and kidney involvement, caused by a homozygous BCS1L mutation (232A>G).

Molecular therapy for obesity and diabetes based on a long‐term increase in hepatic fatty‐acid oxidation

Josep M. Orellana‐Gavaldà, Laura Herrero, Maria Ida Malandrino, Astrid Pañeda, Maria Sol Rodríguez‐Peña, Harald Petry, Guillermina Asins, Sander Van Deventer, Fausto G. Hegardt, Dolors Serra – 22 December 2010 – Obesity‐induced insulin resistance is associated with both ectopic lipid deposition and chronic, low‐grade adipose tissue inflammation. Despite their excess fat, obese individuals show lower fatty‐acid oxidation (FAO) rates. This has raised the question of whether burning off the excess fat could improve the obese metabolic phenotype.

Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis

Andrew D. Yeoman, Rachel H. Westbrook, Yoh Zen, Paola Maninchedda, Bernard C. Portmann, John Devlin, John G. O'Grady, Phillip M. Harrison, Michael A. Heneghan – 22 December 2010 – Autoimmune hepatitis (AIH) typically responds to treatment in 90% of patients. Early prediction of treatment outcome would be advantageous in clinical practice. We evaluated whether parameters at initiation of therapy or changes in these parameters at day 3 and day 7 following corticosteroid initiation predicted treatment failure.

Insurance status and treatment candidacy of hepatitis C patients: Analysis of population‐based data from the United States

Maria Stepanova, Fasiha Kanwal, Hashem B. El‐Serag, Zobair M. Younossi – 17 December 2010 – Successful treatment with antiviral therapy could potentially reduce morbidity and mortality in patients with hepatitis C virus (HCV) infection. However, at the population level, these benefits may be offset by a limited number of patients who have access to antiviral treatment. Using data from the National Health and Nutrition Examination Survey conducted in 2005‐2008, we analyzed the health insurance status and treatment candidacy of HCV‐positive (HCV+) individuals.

Evolution of genomic instability in diethylnitrosamine‐induced hepatocarcinogenesis in mice

Kristina Aleksic, Carolin Lackner, Jochen B. Geigl, Martina Schwarz, Martina Auer, Peter Ulz, Maria Fischer, Zlatko Trajanoski, Marcus Otte, Michael R. Speicher – 17 December 2010 – Diethylnitrosamine (DEN) is a hepatic procarcinogen which is frequently used as an inducer of hepatocellular carcinoma (HCC) in mice. Although mice after DEN exposure are among the most widely used models for liver tumorigenesis, a detailed, mechanistic characterization of the longitudinal changes in the respective tumor genomes has never been performed.

Subscribe to